EXEL – Exelixis, Inc.
EXEL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.37
Margin Of Safety %
Put/Call OI Ratio
0.73
EPS Next Q Diff
0.03
EPS Last/This Y
0.69
EPS This/Next Y
0.48
Price
49.46
Target Price
49.06
Analyst Recom
2.1
Performance Q
15.08
Upside
34.3%
Beta
0.39
Ticker: EXEL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-13 | EXEL | 44.99 | 0.79 | 0.14 | 25459 |
| 2026-04-14 | EXEL | 45.87 | 0.77 | 0.56 | 25966 |
| 2026-04-15 | EXEL | 44.29 | 0.76 | 0.68 | 26231 |
| 2026-04-17 | EXEL | 44.9 | 0.77 | 0.06 | 26663 |
| 2026-04-20 | EXEL | 43.59 | 0.74 | 0.83 | 24383 |
| 2026-04-21 | EXEL | 45.89 | 0.75 | 0.58 | 24898 |
| 2026-04-23 | EXEL | 46.07 | 0.73 | 0.12 | 25776 |
| 2026-04-24 | EXEL | 44.95 | 0.72 | 0.84 | 25829 |
| 2026-04-27 | EXEL | 44.64 | 0.73 | 1.07 | 25980 |
| 2026-04-28 | EXEL | 44.95 | 0.73 | 1.03 | 25951 |
| 2026-04-29 | EXEL | 44.85 | 0.73 | 7.44 | 26002 |
| 2026-04-30 | EXEL | 44.45 | 0.73 | 2.49 | 25973 |
| 2026-05-01 | EXEL | 43.68 | 0.73 | 0.18 | 25972 |
| 2026-05-04 | EXEL | 44.42 | 0.73 | 0.66 | 26023 |
| 2026-05-05 | EXEL | 44.42 | 0.73 | 0.70 | 26195 |
| 2026-05-06 | EXEL | 48.69 | 0.74 | 0.18 | 27171 |
| 2026-05-07 | EXEL | 46.6 | 0.70 | 0.68 | 28517 |
| 2026-05-08 | EXEL | 48.16 | 0.73 | 1.40 | 30539 |
| 2026-05-11 | EXEL | 49.73 | 0.72 | 0.03 | 30676 |
| 2026-05-12 | EXEL | 49.74 | 0.73 | 0.15 | 30518 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-13 | EXEL | 44.97 | 22.2 | -35.8 | 3.40 |
| 2026-04-14 | EXEL | 45.87 | 22.7 | -17.4 | 3.40 |
| 2026-04-15 | EXEL | 44.28 | 22.7 | -50.0 | 3.40 |
| 2026-04-16 | EXEL | 44.39 | 22.7 | -47.9 | 3.40 |
| 2026-04-17 | EXEL | 44.90 | 22.2 | -57.7 | 3.39 |
| 2026-04-20 | EXEL | 43.62 | 22.2 | -83.5 | 3.39 |
| 2026-04-21 | EXEL | 45.89 | 23.4 | -37.7 | 3.43 |
| 2026-04-22 | EXEL | 46.86 | 23.4 | -18.2 | 3.43 |
| 2026-04-23 | EXEL | 46.05 | 23.1 | -34.5 | 3.43 |
| 2026-04-24 | EXEL | 44.96 | 23.1 | -56.5 | 3.43 |
| 2026-04-27 | EXEL | 44.65 | 23.1 | -62.7 | 3.43 |
| 2026-04-28 | EXEL | 44.93 | 23.1 | -57.1 | 3.44 |
| 2026-04-30 | EXEL | 44.47 | 23.1 | -66.4 | 3.44 |
| 2026-05-01 | EXEL | 43.67 | 23.1 | -82.5 | 3.44 |
| 2026-05-04 | EXEL | 44.14 | 23.1 | -73.0 | 3.44 |
| 2026-05-05 | EXEL | 44.44 | 23.1 | -67.0 | 3.44 |
| 2026-05-06 | EXEL | 48.69 | 23.1 | 12.6 | 3.44 |
| 2026-05-07 | EXEL | 46.23 | 10.7 | - | 3.47 |
| 2026-05-08 | EXEL | 48.16 | 10.7 | - | 3.47 |
| 2026-05-11 | EXEL | 49.73 | 14.4 | - | 3.57 |
| 2026-05-12 | EXEL | 49.46 | 14.4 | - | 3.57 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-13 | EXEL | -7.36 | 3.07 | 10.86 |
| 2026-04-14 | EXEL | -7.36 | 3.07 | 10.86 |
| 2026-04-15 | EXEL | -7.36 | 3.07 | 10.86 |
| 2026-04-16 | EXEL | -7.36 | 3.07 | 10.86 |
| 2026-04-17 | EXEL | -7.36 | 3.07 | 10.86 |
| 2026-04-20 | EXEL | -7.36 | 3.25 | 10.86 |
| 2026-04-21 | EXEL | -7.36 | 3.25 | 10.86 |
| 2026-04-22 | EXEL | -7.36 | 3.25 | 10.87 |
| 2026-04-23 | EXEL | -7.08 | 3.25 | 10.87 |
| 2026-04-24 | EXEL | -7.23 | 3.25 | 11.12 |
| 2026-04-27 | EXEL | -7.23 | 3.63 | 11.54 |
| 2026-04-28 | EXEL | -7.23 | 3.63 | 11.54 |
| 2026-04-29 | EXEL | -7.23 | 3.63 | 11.54 |
| 2026-04-30 | EXEL | -7.23 | 3.63 | 11.54 |
| 2026-05-01 | EXEL | -7.23 | 3.63 | 11.54 |
| 2026-05-04 | EXEL | -7.23 | 3.54 | 11.54 |
| 2026-05-05 | EXEL | -7.23 | 3.54 | 11.54 |
| 2026-05-06 | EXEL | -7.23 | 3.54 | 11.54 |
| 2026-05-07 | EXEL | -7.23 | 3.54 | 11.54 |
| 2026-05-08 | EXEL | -7.30 | 3.54 | 11.67 |
| 2026-05-11 | EXEL | -8.16 | 3.19 | 11.67 |
| 2026-05-12 | EXEL | -8.16 | 3.19 | 12.37 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.87
Avg. EPS Est. Current Quarter
0.86
Avg. EPS Est. Next Quarter
0.9
Insider Transactions
-8.16
Institutional Transactions
3.19
Beta
0.39
Average Sales Estimate Current Quarter
632
Average Sales Estimate Next Quarter
660
Fair Value
49.51
Quality Score
92
Growth Score
97
Sentiment Score
97
Actual DrawDown %
2
Max Drawdown 5-Year %
-41.5
Target Price
49.06
P/E
16.39
Forward P/E
12.39
PEG
0.87
P/S
5.23
P/B
6.48
P/Free Cash Flow
13.55
EPS
3.02
Average EPS Est. Cur. Y
3.57
EPS Next Y. (Est.)
4.05
Target Price Estimates Raised
2
Target Price Estimates Lowered
Profit Margin
35.08
Relative Volume
0.98
Return on Equity vs Sector %
16.2
Return on Equity vs Industry %
31.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.17
EBIT Estimation
◆
EXEL
Healthcare
$49.46
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
64.2
Range 1M
88%
Sup Dist
2%
Momentum Growth
Ride accelerating trends
WATCH
EPS Yr
13.4%
EPS NY
14.3%
52W%
95%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+39.9% upside
Upside
+39.9%
Quality
92
MoS
0%
Exelixis, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1077
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
EXEL
Latest News
—
Caricamento notizie per EXEL…
stock quote shares EXEL – Exelixis, Inc. Stock Price stock today
news today EXEL – Exelixis, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EXEL – Exelixis, Inc. yahoo finance google finance
stock history EXEL – Exelixis, Inc. invest stock market
stock prices EXEL premarket after hours
ticker EXEL fair value insiders trading